Displaying 171 - 175 of 204
Wed 24 April 2013
The All Party Parliamentary Group on pancreatic cancer (APPG) has announced the launch of a special inquiry. It will look at pancreatic cancer survival rates and investigate why rates of survival from the disease, at around 4%, remain the lowest of all the 21 most common cancers in the UK.Read More about 'Parliamentary inquiry into pancreatic cancer launched'
Tue 16 April 2013
National charity Pancreatic Cancer UK has launched the first regular Live Chat service in the UK, dedicated to those affected by pancreatic cancer.Read More about 'Plugging the support gap for patients and carers'
Thu 21 March 2013
Progress on tackling pancreatic cancer continues to lag behind other cancers despite being the 5th most common cause of cancer death in the UK.Read More about 'Progress on pancreatic cancer still lags behind other cancers'
Wed 23 January 2013
Further details of a 2012 study have shown patients who received Abraxane in combination with the chemotherapy agent gemcitabine had an overall survival of 8.5 months.Read More about 'Cancer drug extends survival by nearly two months'
Mon 12 November 2012
In a Phase III study, Celgene's ABRAXANE® (NAB-PACLITAXEL), currently approved for breast and lung cancer, has been found to improve overall survival for patients with advanced pancreatic cancer.Read More about 'Cancer drug extends survival in patients with advanced pancreatic cancer'